Lower serum levels of IL-13 is associated with increased carotid intima-media thickness in old age subjects

Boccardi, Virginia; Paolacci, Lucia; Croce, Michele Francesco; Baroni, Marta; Ercolani, Sara; Cecchetti, Roberta; Villa, Alejandra; Mecocci, Patrizia

doi:10.1007/s40520-019-01313-4

Cited by 4 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, IL-7 was shown to be significantly reduced by lomitapide that also partially affected IL-15 expression, these changes may target the inflammation mediated CD28 null T cells. However, not all observed changes indicated a positive effect of lomitapide on inflammatory cytokines; for instance, IL-13 was reduced by lomitapide, an anti-inflammatory cytokine that negatively correlates with intima-media thickness (IMT), a surrogate marker for subclinical atherosclerosis [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Lupo

Arcidiacono

Zaramella

et al. 2021

Atherosclerosis Plus

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Lupo

Arcidiacono

Zaramella

et al. 2021

Atherosclerosis Plus

View full text Add to dashboard Cite

“…In addition, IL-5 upregulates the expression of ATP-binding cassette transporter A1 (ABCA1) by regulating the miR-211/JAK2/STAT3 signaling pathway to promote cholesterol efflux ( Chen et al, 2020 ). In a retrospective study, lower levels of IL-13 were found to be associated with higher carotid intima-media thickness values ( Boccardi et al, 2020 ). This suggests that IL-13 deficiency accelerates the progression of AS.…”

Section: Role Of Immune Cells In Asmentioning

confidence: 99%

Targeting gut microbiota and immune crosstalk: potential mechanisms of natural products in the treatment of atherosclerosis

Jing,

Guo,

Dai

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Atherosclerosis (AS) is a chronic inflammatory reaction that primarily affects large and medium-sized arteries. It is a major cause of cardiovascular disease and peripheral arterial occlusive disease. The pathogenesis of AS involves specific structural and functional alterations in various populations of vascular cells at different stages of the disease. The immune response is involved throughout the entire developmental stage of AS, and targeting immune cells presents a promising avenue for its treatment. Over the past 2 decades, studies have shown that gut microbiota (GM) and its metabolites, such as trimethylamine-N-oxide, have a significant impact on the progression of AS. Interestingly, it has also been reported that there are complex mechanisms of action between GM and their metabolites, immune responses, and natural products that can have an impact on AS. GM and its metabolites regulate the functional expression of immune cells and have potential impacts on AS. Natural products have a wide range of health properties, and researchers are increasingly focusing on their role in AS. Now, there is compelling evidence that natural products provide an alternative approach to improving immune function in the AS microenvironment by modulating the GM. Natural product metabolites such as resveratrol, berberine, curcumin, and quercetin may improve the intestinal microenvironment by modulating the relative abundance of GM, which in turn influences the accumulation of GM metabolites. Natural products can delay the progression of AS by regulating the metabolism of GM, inhibiting the migration of monocytes and macrophages, promoting the polarization of the M2 phenotype of macrophages, down-regulating the level of inflammatory factors, regulating the balance of Treg/Th17, and inhibiting the formation of foam cells. Based on the above, we describe recent advances in the use of natural products that target GM and immune cells crosstalk to treat AS, which may bring some insights to guide the treatment of AS.

show abstract

IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages

Scott,

Lewis,

Zhu

et al. 2023

Sci Rep

View full text Add to dashboard Cite

In cardiovascular disease, pathological and protective roles are reported for the Th2 cytokines IL-4 and IL-13, respectively. We hypothesised that differential effects on macrophage function are responsible. Type I and II receptor subunit (IL-2Rγ, IL-4Rα and IL-13Rα1) and M2 marker (MRC-1, CCL18, CCL22) expression was assessed via RT-qPCR in IL-4- and IL-13-treated human primary macrophages. Downstream signalling was evaluated via STAT1, STAT3 and STAT6 inhibitors, and IL-4- and IL-13-induced reactive oxygen species (ROS) generation assessed. IL-4 and IL-13 exhibited equivalent potency and efficacy for M2 marker induction, which was attenuated by STAT3 inhibition. Both cytokines enhanced PDBu-stimulated superoxide generation however this effect was 17% greater with IL-4 treatment. Type I IL-4 receptor expression was increased on M1-like macrophages but did not lead to a differing ability of these cytokines to modulate M1-like macrophage superoxide production. Overall, this study did not identify major differences in the ability of IL-4 and IL-13 to modulate macrophage function, suggesting that the opposing roles of these cytokines in cardiovascular disease are likely to be via actions on other cell types. Future studies should directly compare IL-4 and IL-13 in vivo to more thoroughly investigate the therapeutic validity of selective targeting of these cytokines.

show abstract

Lower serum levels of IL-13 is associated with increased carotid intima-media thickness in old age subjects

Cited by 4 publications

References 23 publications

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Targeting gut microbiota and immune crosstalk: potential mechanisms of natural products in the treatment of atherosclerosis

IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages

Contact Info

Product

Resources

About